Haruki Koike

List of Publications by Year
in descending order

151 papers	6,126 citations	81900 39 h-index	85541 71 g-index
159 all docs	159 docs citations	159 times ranked	4714 citing authors

#	Article	IF	Citations
1	ANCA-Associated Vasculitic Neuropathies: A Review. Neurology and Therapy, 2022, 11, 21-38.	3.2	17
2	Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies. Neuromuscular Disorders, 2022, 32, 503-511.	0.6	2
3	InÂvivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: An ultrastructural study. Allergology International, 2022, 71, 373-382.	3.3	11
4	Role of complement components in vasculitic neuropathy associated with systemic lupus erythematosus and rheumatoid arthritis. Muscle and Nerve, 2022, 66, 175-182.	2.2	6
5	Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Science Advances, 2022, 8, .	10.3	15
6	Early ultrastructural lesions of antiâ€neutrophil cytoplasmic antibodyâ€versus complementâ€associated vasculitis. Neuropathology, 2022, 42, 420-429.	1.2	9
7	Clinical implication of denervation in sporadic inclusion body myositis. Journal of the Neurological Sciences, 2022, 439, 120317.	0.6	3
8	The wide-ranging clinical and genetic features in Japanese families with valosin-containing protein proteinopathy. Neurobiology of Aging, 2021, 100, 120.e1-120.e6.	3.1	8
9	Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. Journal of the Neurological Sciences, 2021, 421, 117305.	0.6	6
10	Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1072-1079.	1.9	10
11	Macrophages and Autoantibodies in Demyelinating Diseases. Cells, 2021, 10, 844.	4.1	26
12	The role of macrophages in Guillainâ€BarrÃ© syndrome and chronic inflammatory demyelinating polyneuropathy. Neurology and Clinical Neuroscience, 2021, 9, 203-210.	0.4	7
13	Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. Journal of Neurology, 2021, 268, 3835-3844.	3.6	14
14	Emerging infectious diseases, vaccines and Guillainâ€“BarrÃ© syndrome. Clinical and Experimental Neuroimmunology, 2021, 12, 165-170.	1.0	7
15	Emerging Infection, Vaccination, and Guillainâ€“BarrÃ© Syndrome: A Review. Neurology and Therapy, 2021, 10, 523-537.	3.2	40
16	Multidisciplinary Approaches for Transthyretin Amyloidosis. Cardiology and Therapy, 2021, 10, 289-311.	2.6	28
17	The Ultrastructure of Tissue Damage by Amyloid Fibrils. Molecules, 2021, 26, 4611.	3.8	17
18	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. Molecules, 2021, 26, 5091.	3.8	23

#	Article	IF	Citations
19	Paraproteinemia and neuropathy. Neurological Sciences, 2021, 42, 4489-4501.	1.9	8
20	Nerve biopsy in acquired neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S21-S41.	3.1	2
21	Association Between IL-5 Levels and the Clinicopathologic Features of Eosinophilic Granulomatosis With Polyangiitis. Neurology, 2021, 96, 226-229.	1.1	5
22	Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M. Frontiers in Aging Neuroscience, 2021, 13, 786322.	3.4	8
23	Demyelinating Neuropathy Due to Intravascular Large B-cell Lymphoma. Internal Medicine, 2020, 59, 435-438.	0.7	6
24	Expanding the spectrum of transthyretin amyloidosis. Muscle and Nerve, 2020, 61, 3-4.	2.2	2
25	Complement deposition and macrophage-induced demyelination in CIDP with anti-LM1 antibodies. Journal of the Neurological Sciences, 2020, 408, 116509.	0.6	14
26	Aberrant Expression of Nodal and Paranodal Molecules in Neuropathy Associated With IgM Monoclonal Gammopathy With Anti-Myelin-Associated Glycoprotein Antibodies. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1303-1312.	1.7	8
27	Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies. Neurology and Therapy, 2020, 9, 317-333.	3.2	59
28	Patisiran, an RNAi therapeutic for patients with hereditary transthyretinâ€mediated amyloidosis: Subâ€analysis in Japanese patients from the APOLLO study. Neurology and Clinical Neuroscience, 2020, 8, 251-260.	0.4	3
29	Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. Neurology and Therapy, 2020, 9, 213-227.	3.2	41
30	Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. Journal of the Neurological Sciences, 2020, 414, 116813.	0.6	19
31	Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology, 2020, 94, e1726-e1737.	1.1	58
32	Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-BarrÃ© syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 650-659.	1.9	31
33	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Research Protocols, 2020, 9, e17117.	1.0	23
34	Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nature Genetics, 2019, 51, 1215-1221.	21.4	328
35	Cardiac and peripheral vasomotor autonomic functions in hereditary transthyretin amyloidosis with non-Val30Met mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 13-14.	3.0	1
36	Cardiovascular autonomic functions in late-onset hereditary transthyretin amyloidosis with Val30Met mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 6-6.	3.0	1

#	Article	IF	Citations
37	Common clinicopathological features in late-onset hereditary transthyretin amyloidosis (Ala97Gly,) Tj ETQq1 1 0.784314 rgBT /Overlock the Official Journal of the International Society of Amyloidosis, 2019, 26, 24-25.	3.0	4
38	Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 26-26.	3.0	0
39	Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nature Reviews Neurology, 2019, 15, 387-404.	10.1	267
40	Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 988-996.	1.9	56
41	Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis. Neurology and Clinical Neuroscience, 2019, 7, 166-173.	0.4	6
42	Myelopathy and Neuropathy Associated With Alcoholism. , 2019, , 195-205.		4
43	Vasculitic neuropathy with antiâ€phosphatidylserine/prothrombin complex antibody. Muscle and Nerve, 2019, 59, E44-E46.	2.2	0
44	Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights. Biomedicines, 2019, 7, 11.	3.2	50
45	New teased-fibre definitions represent specific mechanisms of neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 124-124.	1.9	0
46	III. Metabolic, Nutritional, and Drug-induced Neuropathies. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1530-1537.	0.0	0
47	Deciphering the mechanism and spectrum of chronic inflammatory demyelinating polyneuropathy using morphology. Clinical and Experimental Neuroimmunology, 2018, 9, 35-46.	1.0	7
48	Safety and efficacy of eculizumab in Guillain-BarrÃ© syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurology, The, 2018, 17, 519-529.	10.2	111
49	First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 8-10.	3.0	42
50	Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology, 2018, 91, 1051-1060.	1.1	64
51	Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis. Internal Medicine, 2018, 57, 3365-3370.	0.7	14
52	Recurrent autonomic and sensory neuropathy in a patient with anti-ganglionic acetylcholine receptor antibodies. ENeurologicalSci, 2018, 12, 36-38.	1.3	2
53	The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study. Journal of the Neurological Sciences, 2018, 394, 99-106.	0.6	32
54	Restoration of a Conduction Block after the Long-term Treatment of CIDP with Anti-neurofascin 155 Antibodies: Follow-up of a Case over 23 Years. Internal Medicine, 2018, 57, 2061-2066.	0.7	11

#	Article	IF	Citations
55	Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet Journal of Rare Diseases, 2018, 13, 6.	2.7	104
56	Systemic angiopathy and axonopathy in hereditary transthyretin amyloidosis with Ala97Gly (p.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 71 Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 141-142.	3.0	6
57	Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 465-473.	1.9	151
58	Disruption of bloodâ€“nerve barriers in hereditary transthyretin (ATTR) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 89-90.	3.0	1
59	Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy. Journal of Neurology, 2017, 264, 2293-2302.	3.6	15
60	Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e407.	6.0	18
61	Reply: Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. Brain, 2017, 140, e52-e52.	7.6	12
62	Transforming growth factorâ€î² signaling is upregulated in sporadic inclusion body myositis. Muscle and Nerve, 2017, 55, 741-747.	2.2	9
63	Vasculitic Neuropathy Following Exposure to a Glyphosate-based Herbicide. Internal Medicine, 2017, 56, 1431-1434.	0.7	16
64	Alcoholic Myelopathy and Nutritional Deficiency. Internal Medicine, 2017, 56, 105-108.	0.7	5
65	Association of leptin with orthostatic blood pressure changes in Parkinson's disease. Movement Disorders, 2016, 31, 1417-1421.	3.9	15
66	Gene Expression Profile of Inflammatory Myopathy with Malignancy is Similar to that of Dermatomyositis rather than Polymyositis. Internal Medicine, 2016, 55, 2571-2580.	0.7	8
67	Intraepidermal nerve fibre density in POEMS (Crow-Fukase) syndrome and the correlation with sural nerve pathology. Journal of the Neurological Sciences, 2016, 365, 207-211.	0.6	3
68	Guillainâ€“BarrÃ© syndrome after allogeneic bone marrow transplantation: Case report and literature review. ENeurologicalSci, 2016, 4, 52-55.	1.3	7
69	Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2016, 15, 1129-1137.	10.2	66
70	Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 571-579.	1.7	23
71	IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. Journal of Neuroimmunology, 2016, 301, 16-22.	2.3	70
72	Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain, 2016, 139, 3170-3186.	7.6	268

#	Article	IF	Citations
73	Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology, 2016, 87, 2220-2229.	1.1	85
74	Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy. PLoS ONE, 2016, 11, e0168846.	2.5	22
75	A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-BarrÃ© Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols, 2016, 5, e210.	1.0	18
76	Uncompacted Myelin Lamellae and Nodal Ion Channel Disruption in POEMS Syndrome. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1127-1136.	1.7	2
77	Uncompacted Myelin Lamellae and Nodal Ion Channel Disruption in POEMS Syndrome. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1127-1136.	1.7	12
78	Two brothers homozygous for the TTR V30M both presenting with a phenotype dominated by central nervous complications. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 261-262.	3.0	3
79	Efficacy of intravenous immunoglobulin for treatment of Lambertâ€“Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: A case report. Neuromuscular Disorders, 2015, 25, 70-72.	0.6	5
80	Clinicopathologic features of folate-deficiency neuropathy. Neurology, 2015, 84, 1026-1033.	1.1	60
81	Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody. Journal of the Neurological Sciences, 2015, 348, 67-73.	0.6	24
82	Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome): a multicenter, double-blind trial. Journal of Neurology, 2015, 262, 752-759.	3.6	42
83	Clinicopathological features of sarcoidosis manifesting as generalized chronic myopathy. Journal of Neurology, 2015, 262, 1035-1045.	3.6	34
84	Clinicopathologic features of folate-deficiency neuropathy. Neurology, 2015, 85, 1090-1091.	1.1	4
85	Immunoglobulin G4-related pathologic features in inflammatory neuropathies. Neurology, 2015, 85, 1400-1407.	1.1	22
86	Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open, 2014, 4, e005213.	1.9	52
87	Muscle atrophy in chronic inflammatory demyelinating polyneuropathy: a computed tomography assessment. European Journal of Neurology, 2014, 21, 1002-1010.	3.3	15
88	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	1.9	22
89	Cutaneous arteritis associated with peripheral neuropathy: Two case reports. Journal of Dermatology, 2014, 41, 266-267.	1.2	4
90	<scp>S</scp>chwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3. Neuropathology and Applied Neurobiology, 2014, 40, 628-639.	3.2	15

#	Article	IF	Citations
91	Neuronal intranuclear inclusion disease cases with leukoencephalopathy diagnosed via skin biopsy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 354-356.	1.9	106
92	Mononeuritis multiplex with tumefactive cellular infiltration in a patient with reactive lymphoid hyperplasia with increased immunoglobulin G4â€“positive cells. Human Pathology, 2014, 45, 427-430.	2.0	9
93	Slowly progressive folate-deficiency myelopathy: Report of a case. Journal of the Neurological Sciences, 2014, 336, 273-275.	0.6	11
94	What is the prototype of familial amyloid polyneuropathy?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 713-713.	1.9	2
95	Paraneoplastic neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 713-726.	1.8	48
96	Clinicopathological features of neuropathy associated with lymphoma. Brain, 2013, 136, 2563-2578.	7.6	146
97	Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: A proteomic approach. International Journal of Cardiology, 2013, 170, 69-74.	1.7	32
98	Autonomic manifestations in acute sensory ataxic neuropathy: A case report. Autonomic Neuroscience: Basic and Clinical, 2013, 179, 155-158.	2.8	7
99	Wide range of clinicopathological features in immuneâ€mediated autonomic neuropathies. Clinical and Experimental Neuroimmunology, 2013, 4, 46-59.	1.0	2
100	Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Nephrology, 2013, 17, 683-685.	1.6	25
101	The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 98-106.	1.9	76
102	IgG4-Related Neuropathy. JAMA Neurology, 2013, 70, 502.	9.0	40
103	Demographic Features of Japanese Patients with Sporadic Inclusion Body Myositis: A Single-center Referral Experience. Internal Medicine, 2013, 52, 333-337.	0.7	18
104	Differential Recovery in Cardiac and Vasomotor Sympathetic Functional Markers in a Patient with Acute Autonomic Sensory and Motor Neuropathy. Internal Medicine, 2013, 52, 497-502.	0.7	5
105	Demyelinating Neuropathy and Autoimmune Hemolytic Anemia in a Patient with Pancreatic Cancer. Internal Medicine, 2013, 52, 1737-1740.	0.7	9
106	Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 152-158.	1.9	169
107	Late-onset familial amyloid polyneuropathy in Japan. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 55-57.	3.0	20
108	Impact of aging on the progression of neuropathy after liver transplantation in transthyretin Val30Met amyloidosis. Muscle and Nerve, 2012, 46, 961-964.	2.2	9

#	Article	IF	Citations
109	The spectrum of clinicopathological features in pure autonomic neuropathy. Journal of Neurology, 2012, 259, 2067-2075.	3.6	24
110	A novel MPZ mutation in Charcotâ€“Marieâ€“Tooth disease type 1B with focally folded myelin and multiple entrapment neuropathies. Neuromuscular Disorders, 2012, 22, 166-169.	0.6	6
111	Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary SjÃ¶gren's syndrome-associated neuropathy. Journal of the Neurological Sciences, 2012, 319, 139-146.	0.6	28
112	The significance of folate deficiency in alcoholic and nutritional neuropathies: Analysis of a case. Nutrition, 2012, 28, 821-824.	2.4	16
113	Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 53-62.	3.0	98
114	Paraneoplastic neuropathy. Current Opinion in Neurology, 2011, 24, 504-510.	3.6	137
115	Spatial Distribution of Nerve Fiber Pathology and Vasculitis in Microscopic Polyangiitis-Associated Neuropathy. Journal of Neuropathology and Experimental Neurology, 2011, 70, 340-348.	1.7	35
116	The Wide Range of Clinical Manifestations in Leprous Neuropathy: Two Case Reports. Internal Medicine, 2011, 50, 2223-2226.	0.7	5
117	Polymorphism of transient axonal glycoproteinâ€1 in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2011, 16, 52-55.	3.1	15
118	Acute superficial sensory neuropathy with generalized anhidrosis, anosmia, and ageusia. Muscle and Nerve, 2011, 43, 286-288.	2.2	8
119	Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1287-1290.	1.9	27
120	Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 87-90.	3.0	17
121	Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance Anti-Myelin-Associated Glycoprotein Neuropathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1143-1157.	1.7	48
122	2. Peripheral Nervous System. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1853-1857.	0.0	0
123	IgM MGUS antiâ€MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle and Nerve, 2010, 42, 433-435.	2.2	23
124	Slowly progressive autonomic neuropathy with antiganglionic acetylcholine receptor antibody. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 586-587.	1.9	18
125	Diagnosis of familial amyloid polyneuropathy: wide-ranged clinicopathological features. Expert Opinion on Medical Diagnostics, 2010, 4, 323-331.	1.6	11
126	Clinicopathological features of acute autonomic and sensory neuropathy. Brain, 2010, 133, 2881-2896.	7.6	84

#	Article	IF	Citations
127	Expanding the concept of inflammatory neuropathies. Brain, 2010, 133, 2848-2851.	7.6	3
128	Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy. Journal of Clinical Neuroscience, 2010, 17, 1003-1008.	1.5	7
129	Intravenous immunoglobulin treatment for painful sensory neuropathy associated with SjÃ¶gren's syndrome. Journal of the Neurological Sciences, 2009, 279, 57-61.	0.6	74
130	Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. Journal of the Neurological Sciences, 2009, 287, 178-184.	0.6	84
131	The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 142-148.	3.0	31
132	Intravenous immunoglobulin therapy in proximal diabetic neuropathy. BMJ Case Reports, 2009, 2009, bcr0820080656-bcr0820080656.	0.5	3
133	Hypophosphataemic neuropathy during total parenteral nutrition. BMJ Case Reports, 2009, 2009, bcr0820080718-bcr0820080718.	0.5	1
134	Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. Journal of Neurology, 2008, 255, 1526-1533.	3.6	55
135	Rapidly developing weakness mimicking Guillain-BarrÃ© syndrome in beriberi neuropathy: Two case reports. Nutrition, 2008, 24, 776-780.	2.4	49
136	Small neurons may be preferentially affected in ganglionopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 113-113.	1.9	18
137	Metabolic and nutritional neuropathy. Clinical Neurology, 2008, 48, 1026-1027.	0.1	3
138	Hypophosphataemic neuropathy in a patient who received intravenous hyperalimentation. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1159-1160.	1.9	5
139	Nonmyelinating Schwann Cell Involvement With Well-Preserved Unmyelinated Axons in Charcot-Marie-Tooth Disease Type 1A. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1027-1036.	1.7	32
140	Myopathy in thiamine deficiency: Analysis of a case. Journal of the Neurological Sciences, 2006, 249, 175-179.	0.6	24
141	Alcoholic neuropathy. Current Opinion in Neurology, 2006, 19, 481-486.	3.6	157
142	The wide spectrum of clinical manifestations in SjÃ¶gren's syndrome-associated neuropathy. Brain, 2005, 128, 2518-2534.	7.6	485
143	Postgastrectomy polyneuropathy with thiamine deficiency is identical to beriberi neuropathy. Nutrition, 2004, 20, 961-966.	2.4	45
144	Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Annals of Neurology, 2003, 54, 19-29.	5.3	222

#	Article	IF	Citations
145	Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain, 2003, 126, 134-151.	7.6	202
146	Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 32-38.	3.0	28
147	Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals. Journal of the Peripheral Nervous System, 2002, 7, 221-224.	3.1	90
148	Type I (Transthyretin Met30) Familial Amyloid Polyneuropathy in Japan. Archives of Neurology, 2002, 59, 1771.	4.5	221
149	Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. Journal of Rheumatology, 2002, 29, 1408-14.	2.0	49
150	Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2001, 184, 57-63.	0.6	78
151	Differential response to corticosteroid therapy of MRI findings and clinical manifestations in spinal cord sarcoidosis. Journal of Neurology, 2000, 247, 544-549.	3.6	33